Brendan D. Curti, MD
Portland, OR 97213
Providence Cancer Institute Franz Clinic
4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213
Insurances Accepted
This information provides an overview of accepted insurance plan types for new patients. Coverage may vary by specific plan. Please verify with your insurance provider before visiting us for care. Established patients should call to verify insurance acceptance.
About Brendan D. Curti
Dr. Curti was a Senior Investigator at the National Cancer Institute and was an Associate Professor at the Penn State College of Medicine before joining Providence Cancer Institute and Earle A. Chiles Research Institute. He now serves as the Director of the Melanoma Program, Cytokine and Adoptive Immunotherapy and Genitourinary Oncology Research at the Providence Cancer Institute.
He is the first recipient of the Robert W. Franz Endowed Chair for Clinical Research at Providence. His research and clinical focus is translational research - taking ideas in the lab and applying them to improve care for our patients with melanoma and genitourinary malignancy. Dr. Curti sees patients in Portland, OR.
Georgetown University
1985
Georgetown University
1990
Penn State Milton S. Hershey Medical Center
1988
American Society for Clinical Oncology (ASCO)
American Society for Cancer Research (AACR)
Society for the Immunotherapy of Cancer (SITC)
- American Board of Internal Medicine, Internal Medicine
- Immunotherapy in Advanced Renal Cancer - Is Cure Possible?
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
- Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
- OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
- Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.
- Clinical deployment of antibodies for treatment of melanoma.
- The high-dose aldesleukin \select\ trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
- Rapid evolution of combination therapy in melanoma.
- OX40 is a potent immune-stimulating target in late-stage cancer patients
- Integrating new therapies in the treatment of advanced melanoma.
- Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
- Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG.
- Science gone translational: the OX40 agonist story.
- Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
- Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
- Sunitinib efficacy against advanced renal cell carcinoma.
- Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.
- Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.
- Sunitinib in patients with metastatic renal cell carcinoma.
- A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
- Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
- Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
- Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
- Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
- Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
- A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
- Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin.
- Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus.
- Interleukin 1 alpha increases serum leptin concentrations in humans.
- Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
4805 Northeast Glisan Street, Suite 11N-1
Portland, OR 97213
Providence Medical Group - Oregon
Providence St. Vincent Medical Center
Providence Milwaukie Hospital
Providence Hood River Memorial Hospital
Providence Newberg Medical Center
Providence Willamette Falls Medical Center
Community Reviews
At Providence, we're dedicated to providing you quality, personalized health care. We are constantly striving to optimize your experience.
As part of ensuring you have a positive experience with Providence, our online provider directory includes ratings and patient comments for select providers. More about our survey.
Great oncologist and scientist. I will miss him.
Providence Patient
Thank you Dr. Curti! You will be missed!
Providence Patient
Dr Curti is the BEST!! Excellent caregiver always makes sure my questions are answered. Goes extra in answering questions. Excellent Ambassador for Providence. I fly across the country to see him!! It would be much easier and less expensive to have all my care delivered closer to home but traveling to see him is WELL worth any expense and inconvenience !
Providence Patient
Excellent as always
Providence Patient
Dr Curti is a great doctor
Providence Patient
This was my final visit with Dr Curti before his retirement. I always felt well cared for by him, and will miss him as I transition to a new oncologist.
Providence Patient